MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into a definitive agreement with several accredited and institutional investors for the sale of 685,033 shares of the…Read More
BioRestorative Therapies Announces 21 Million Registered Direct Offering
